Brokerages Set SAB Biotherapeutics, Inc. (NASDAQ:SABS) Price Target at $10.50

SAB Biotherapeutics, Inc. (NASDAQ:SABS) has been given an average rating of “Moderate Buy” by the eight ratings firms that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $10.50.

A number of brokerages have recently weighed in on SABS. Weiss Ratings reiterated a “sell (d+)” rating on shares of SAB Biotherapeutics in a research note on Friday, April 10th. Rodman & Renshaw began coverage on SAB Biotherapeutics in a research note on Thursday, April 2nd. They set a “buy” rating and a $13.00 target price on the stock. Chardan Capital increased their target price on SAB Biotherapeutics from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, March 11th. Wall Street Zen lowered SAB Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. Finally, Zacks Research lowered SAB Biotherapeutics from a “hold” rating to a “strong sell” rating in a research note on Thursday, March 12th.

SAB Biotherapeutics Price Performance

Shares of NASDAQ SABS opened at $4.11 on Friday. The firm has a market cap of $209.41 million, a P/E ratio of -1.77 and a beta of 0.55. The company has a current ratio of 9.46, a quick ratio of 9.46 and a debt-to-equity ratio of 0.02. SAB Biotherapeutics has a 1-year low of $1.60 and a 1-year high of $6.60. The business’s 50 day moving average is $3.88 and its 200-day moving average is $3.79.

SAB Biotherapeutics (NASDAQ:SABS) last announced its earnings results on Monday, March 9th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.30). Equities research analysts predict that SAB Biotherapeutics will post -1.1 earnings per share for the current year.

Institutional Investors Weigh In On SAB Biotherapeutics

A number of large investors have recently added to or reduced their stakes in SABS. PNC Financial Services Group Inc. acquired a new stake in SAB Biotherapeutics during the first quarter worth approximately $29,000. ADAR1 Capital Management LLC acquired a new stake in SAB Biotherapeutics during the third quarter worth approximately $30,000. Dimensional Fund Advisors LP acquired a new stake in SAB Biotherapeutics during the third quarter worth approximately $32,000. State of Wyoming acquired a new stake in SAB Biotherapeutics during the fourth quarter worth approximately $34,000. Finally, Virtu Financial LLC acquired a new stake in SAB Biotherapeutics during the third quarter worth approximately $40,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.